Literature DB >> 23673001

Primary epiphyseal arteriopathy in a mouse model of steroid-induced osteonecrosis.

Laura J Janke1, Chengcheng Liu, Peter Vogel, Jitesh Kawedia, Kelli L Boyd, Amy J Funk, Mary V Relling.   

Abstract

Patients undergoing glucocorticoid therapy for a variety of disorders, including autoimmune diseases and hematological malignancies, are at risk of developing osteonecrosis. Despite extensive research in both patients and animal models, the underlying pathogenesis remains unclear. Proposed inciting mechanisms include intravascular thrombotic occlusion, marrow fat hypertrophy, osteocyte and/or endothelial cell apoptosis, hypercoagulability, and vasoconstriction of specific arteries and arterioles supplying bone. Our laboratory has developed a model of steroid-induced osteonecrosis in BALBcJ mice which reflects clinically relevant exposures to glucocorticoids in which treated mice develop osteonecrosis of the distal femoral epiphysis when administered 4 to 8 mg/L dexamethasone in drinking water for 6 weeks. We identified lesions in arterioles supplying this area, with the mildest occurring in knees without any evidence of osteonecrosis. However, arteriopathy was more common among mice that did versus did not develop osteonecrosis (P < 0.0001); in mice with osteonecrosis, the associated vessels showed transmural necrosis and thickening of the vessel wall progressing to the point of luminal obstruction. In the most severe cases of osteonecrosis, end-stage lesions consisted of fully occluded vessels with marrow and bone necrosis involving the entire epiphysis. We propose that a primary arteriopathy is the initiating event in the genesis of steroid-induced osteonecrosis and provides a basis for future investigation of this disease process.
Copyright © 2013 American Society for Investigative Pathology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23673001      PMCID: PMC3702740          DOI: 10.1016/j.ajpath.2013.03.004

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  38 in total

1.  Glucocorticoid inhibition of cytokine-induced E-selectin promoter activation.

Authors:  K P Ray; N Searle
Journal:  Biochem Soc Trans       Date:  1997-05       Impact factor: 5.407

2.  Sustained local delivery of dexamethasone by a novel intravascular eluting stent to prevent restenosis in the porcine coronary injury model.

Authors:  A M Lincoff; J G Furst; S G Ellis; R J Tuch; E J Topol
Journal:  J Am Coll Cardiol       Date:  1997-03-15       Impact factor: 24.094

3.  Pharmacokinetic, pharmacodynamic, and pharmacogenetic determinants of osteonecrosis in children with acute lymphoblastic leukemia.

Authors:  Jitesh D Kawedia; Sue C Kaste; Deqing Pei; John C Panetta; Xiangjun Cai; Cheng Cheng; Geoffrey Neale; Scott C Howard; William E Evans; Ching-Hon Pui; Mary V Relling
Journal:  Blood       Date:  2010-12-10       Impact factor: 22.113

4.  Glucocorticoids but not mineralocorticoids modulate endothelin-1 and angiotensin II binding in SHR vascular smooth muscle cells.

Authors:  P H Provencher; J Saltis; J W Funder
Journal:  J Steroid Biochem Mol Biol       Date:  1995-03       Impact factor: 4.292

5.  [A prospective study of steroid-induced osteonecrosis by MRI screening].

Authors:  M Sakamoto
Journal:  Nihon Seikeigeka Gakkai Zasshi       Date:  1994-05

6.  Evaluation of the intraosseous and extraosseous blood supply to the distal femoral condyles.

Authors:  A S Reddy; R W Frederick
Journal:  Am J Sports Med       Date:  1998 May-Jun       Impact factor: 6.202

7.  Effect on intimal hyperplasia of dexamethasone released from coated metal stents compared with non-coated stents in canine femoral arteries.

Authors:  E P Strecker; A Gabelmann; I Boos; C Lucas; Z Xu; J Haberstroh; N Freudenberg; H Stricker; M Langer; E Betz
Journal:  Cardiovasc Intervent Radiol       Date:  1998 Nov-Dec       Impact factor: 2.740

8.  Study on the mechanisms of glucocorticoid-induced hypertension: glucocorticoids increase transmembrane Ca2+ influx in vascular smooth muscle in vivo.

Authors:  L Kornel; A V Prancan; N Kanamarlapudi; J Hynes; E Kuzianik
Journal:  Endocr Res       Date:  1995 Feb-May       Impact factor: 1.720

9.  Substrain-specific differences in survival and osteonecrosis incidence in a mouse model.

Authors:  Jitesh D Kawedia; Laura Janke; Amy J Funk; Laura B Ramsey; Chengcheng Liu; David Jenkins; Kelli L Boyd; Mary V Relling
Journal:  Comp Med       Date:  2012-12       Impact factor: 0.982

10.  Local delivery of dexamethasone for prevention of neointimal proliferation in a rat model of balloon angioplasty.

Authors:  A E Villa; L A Guzman; W Chen; G Golomb; R J Levy; E J Topol
Journal:  J Clin Invest       Date:  1994-03       Impact factor: 14.808

View more
  25 in total

1.  Hypertension is a modifiable risk factor for osteonecrosis in acute lymphoblastic leukemia.

Authors:  Laura J Janke; Sara L Van Driest; Mary V Portera; Ravi V Atreya; Joshua C Denny; Deqing Pei; Cheng Cheng; Sue C Kaste; Hiroto Inaba; Sima Jeha; Ching-Hon Pui; Mary V Relling; Seth E Karol
Journal:  Blood       Date:  2019-08-13       Impact factor: 22.113

2.  Association of toll-like receptor 4 signaling pathway with steroid-induced femoral head osteonecrosis in rats.

Authors:  Lei Tian; Dong-Sheng Zhou; Kun-Zheng Wang; Wei Zhang; Zhi-Bin Shi; Li-Hong Fan; Shui Sun
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2014-10-16

3.  Genetics of pleiotropic effects of dexamethasone.

Authors:  Laura B Ramsey; Stan Pounds; Cheng Cheng; Xueyuan Cao; Wenjian Yang; Colton Smith; Seth E Karol; Chengcheng Liu; John C Panetta; Hiroto Inaba; Jeffrey E Rubnitz; Monika L Metzger; Raul C Ribeiro; John T Sandlund; Sima Jeha; Ching-Hon Pui; William E Evans; Mary V Relling
Journal:  Pharmacogenet Genomics       Date:  2017-08       Impact factor: 2.089

Review 4.  Osteonecrosis in children with acute lymphoblastic leukemia.

Authors:  Marina Kunstreich; Sebastian Kummer; Hans-Juergen Laws; Arndt Borkhardt; Michaela Kuhlen
Journal:  Haematologica       Date:  2016-10-14       Impact factor: 9.941

Review 5.  Osteonecrosis in children and adolescents with acute lymphoblastic leukemia: a therapeutic challenge.

Authors:  Michaela Kuhlen; Marina Kunstreich; Kathinka Krull; Roland Meisel; Arndt Borkhardt
Journal:  Blood Adv       Date:  2017-06-13

6.  Whole-joint magnetic resonance imaging to assess osteonecrosis in pediatric patients with acute lymphoblastic lymphoma.

Authors:  Hiroto Inaba; Olga Varechtchouk; Michael D Neel; Matthew J Ehrhardt; Monika L Metzger; Seth E Karol; Kirsten K Ness; Raul C Ribeiro; Ching-Hon Pui; Mary V Relling; John T Sandlund; Sue C Kaste
Journal:  Pediatr Blood Cancer       Date:  2020-05-30       Impact factor: 3.167

7.  Bloodstream infections exacerbate incidence and severity of symptomatic glucocorticoid-induced osteonecrosis.

Authors:  Emily R Finch; Laura J Janke; Colton A Smith; Seth E Karol; Deqing Pei; Cheng Cheng; Sue C Kaste; Hiroto Inaba; Ching-Hon Pui; Joshua Wolf; Mary V Relling
Journal:  Pediatr Blood Cancer       Date:  2019-02-13       Impact factor: 3.167

8.  Genetic risk factors for the development of osteonecrosis in children under age 10 treated for acute lymphoblastic leukemia.

Authors:  Seth E Karol; Leonard A Mattano; Wenjian Yang; Kelly W Maloney; Colton Smith; ChengCheng Liu; Laura B Ramsey; Christian A Fernandez; Tamara Y Chang; Geoffrey Neale; Cheng Cheng; Elaine Mardis; Robert Fulton; Paul Scheet; F Anthony San Lucas; Eric C Larsen; Mignon L Loh; Elizabeth A Raetz; Stephen P Hunger; Meenakshi Devidas; Mary V Relling
Journal:  Blood       Date:  2015-11-20       Impact factor: 22.113

9.  A Novel Hybrid Compound LLP2A-Ale Both Prevented and Rescued the Osteoporotic Phenotype in a Mouse Model of Glucocorticoid-Induced Osteoporosis.

Authors:  Geetha Mohan; Evan Yu-An Lay; Haley Berka; Lorna Ringwood; Alexander Kot; Haiyan Chen; Wei Yao; Nancy E Lane
Journal:  Calcif Tissue Int       Date:  2016-09-27       Impact factor: 4.333

10.  Genetics of glucocorticoid-associated osteonecrosis in children with acute lymphoblastic leukemia.

Authors:  Seth E Karol; Wenjian Yang; Sara L Van Driest; Tamara Y Chang; Sue Kaste; Erica Bowton; Melissa Basford; Lisa Bastarache; Dan M Roden; Joshua C Denny; Eric Larsen; Naomi Winick; William L Carroll; Cheng Cheng; Deqing Pei; Christian A Fernandez; Chengcheng Liu; Colton Smith; Mignon L Loh; Elizabeth A Raetz; Stephen P Hunger; Paul Scheet; Sima Jeha; Ching-Hon Pui; William E Evans; Meenakshi Devidas; Leonard A Mattano; Mary V Relling
Journal:  Blood       Date:  2015-08-11       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.